Crohn's DiseasePhase 3NCT03105128
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 3 study testing risankizumab IV and risankizumab SC in people with Crohn's Disease, run by AbbVie at 475 sites in 44 countries.
Trial summary
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD). Read more about this study
- Who is it for?
- Ages 16 to 80 years
- Conditions the study is for
- Crohn's Disease
- What is being tested?
- risankizumab IV and risankizumab SC
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 931 participants
- Where
- 475 sitesin 44 countries
- Study dates
- 10 May 2017to 14 Apr 2021
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 80 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Male or female aged >=18 to <= 80 years, or minimum age of adult consent according to local regulations, at the Baseline Visit. Where locally permissible, participants 16 to < 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit.
- Diagnosis of CD for at least 3 months prior to Baseline.
- Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD).
- Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD.
- If female, participant must meet the contraception recommendations.
Who cannot join
- Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.
- Participants with unstable doses of concomitant Crohn's disease therapy.
- Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks prior to Baseline), or any investigational biologic or other agent or procedure within 35 days or 5 half-lives prior to Baseline, whichever is longer.
- Prior exposure to p19 inhibitors (e.g., risankizumab).
- Complications of Crohn's disease.
- Having an ostomy or ileoanal pouch.
- Known active Coronavirus Disease 2019 (COVID-19) infection.
Trial locations and contacts
475 sites in 44 countries.
475 sites in 44 countries
United States117 sites
University of Michigan Health Systems /ID# 157144
Ann Arbor, Michigan, 48109
TX Clinical Research Institute /ID# 159410
Arlington, Texas, 76012
Gastroenterology Associates LLC - Jefferson Hwy /ID# 161956
Baton Rouge, Louisiana, 70809
Inquest Clinical Research /ID# 165695
Baytown, Texas, 77521-2415
Washington Gastroenterology Associates /ID# 162120
Bellevue, Washington, 98004
HP Clinical Research /ID# 162998
Bountiful, Utah, 84010
Seffner Premier Health Care, PA /ID# 162265
Brandon, Florida, 33510
NY Scientific /ID# 158418
Brooklyn, New York, 11235
Saratoga Schenectady Gastroenterology Associates - Burnt Hills /ID# 212036
Burnt Hills, New York, 12027
Texas Digestive Disease Consultants /ID# 209596
Cedar Park, Texas, 78613-5028
Texas Digestive Disease Consultants /ID# 209785
Cedar Park, Texas, 78613-5028
Univ NC Chapel Hill /ID# 154840
Chapel Hill, North Carolina, 27514-4220
Medical University of South Carolina /ID# 212579
Charleston, South Carolina, 29425
Atrium Health Carolinas Medical Center /ID# 158481
Charlotte, North Carolina, 28203
MGG Group Co, Inc.Chevy Chase Clinical Research /ID# 154839
Chevy Chase, Maryland, 20815
Northwestern University Division of GI/Hepatology /ID# 158283
Chicago, Illinois, 60611-2927
The University of Chicago Medical Center /ID# 157141
Chicago, Illinois, 60637-1443
Tri-State Endoscopy /ID# 154933
Cincinnati, Ohio, 45219
Clinical Research of West Florida, Inc /ID# 204859
Clearwater, Florida, 33765
Clinical Research of West Florida, Inc /ID# 207450
Clearwater, Florida, 33765
South Lake Pain Institute, Inc /ID# 162825
Clermont, Florida, 34711
Cleveland Clinic Main Campus /ID# 208171
Cleveland, Ohio, 44195
Peak Gastroenterology Associates, PC /ID# 165834
Colorado Springs, Colorado, 80907
Gastro Center of Maryland /ID# 165004
Columbia, Maryland, 21045
The Ohio State University /ID# 164709
Columbus, Ohio, 43210
Optimed Research, Ltd. /ID# 167901
Columbus, Ohio, 43235
Baylor Scott & White Center for Inflammatory Bowel Diseases /ID# 201848
Dallas, Texas, 75246
Western Connecticut Medical Group /ID# 165849
Danbury, Connecticut, 06810-6000
Hometown Urgent Care and Resea /ID# 170453
Dayton, Ohio, 45424
Universal Axon Clinical Research /ID# 165432
Doral, Florida, 33166
NorthShore University HealthSystem /ID# 158287
Evanston, Illinois, 60201
Plains Clinical Research Center, LLC /ID# 169715
Fargo, North Dakota, 58104-5925
Intercity Advanced Gastroentertology Center /ID# 213399
Fresh Meadows, New York, 11366
DHAT Research Institute /ID# 158217
Garland, Texas, 75044-2208
Gastro One /ID# 154742
Germantown, Tennessee, 38138
Duplicate_Long Island Clinical Research /ID# 154836
Great Neck, New York, 11021-5343
Gastroenterology Associates, P.A. of Greenville /ID# 154911
Greenville, South Carolina, 29615-3593
PennState Milton S.Hershey Med /ID# 154883
Hershey, Pennsylvania, 17033
Clinical Trials America /ID# 158484
Hickory, North Carolina, 28601
Houma Digestive Health Special /ID# 158286
Houma, Louisiana, 70360
Vilo Research Group Inc /ID# 206130
Houston, Texas, 77017-2337
CliniCore International, LLC /ID# 158209
Houston, Texas, 77027-6812
Baylor College of Medicine - Baylor Medical Center /ID# 158212
Houston, Texas, 77030-3411
Precision Research Institute, LLC /ID# 200503
Houston, Texas, 77036
Centex Studies, Inc. - Houston /ID# 200720
Houston, Texas, 77058
Newport Huntington Medica /ID# 213033
Huntington Beach, California, 92648-5994
Nature Coast Clinical Research - Inverness /ID# 159414
Inverness, Florida, 34452-4717
Southern Therapy and Advanced Research (STAR) LLC /ID# 162388
Jackson, Mississippi, 39216
East Tennessee Research Institute /ID# 168737
Johnson City, Tennessee, 37604
Vidant Multispecialty Clinic - Kinston /ID# 161111
Kinston, North Carolina, 28501-1589
SIH Research Mumtaz, Inc /ID# 163082
Kissimmee, Florida, 34741-4161
Las Vegas Medical Research /ID# 160172
Las Vegas, Nevada, 89113
Revival Research Institute, Inc /ID# 210984
Las Vegas, Nevada, 89128-3157
University of Kentucky Chandler Medical Center /ID# 157137
Lexington, Kentucky, 40536
Alliance Medical Research /ID# 163840
Lighthouse PT, Florida, 33064
Atria Clinical Research /ID# 164740
Little Rock, Arkansas, 72209-7040
Rocky Mountain Pediatric Gastroenterology /ID# 207169
Lone Tree, Colorado, 80124-6798
United Medical Doctors /ID# 207040
Los Alamitos, California, 90720-3309
TLC Clinical Research Inc /ID# 212503
Los Angeles, California, 90048
Gastrointestinal Biosciences Clinical Trials, LLC /ID# 162656
Los Angeles, California, 90067-2001
University of Louisville /ID# 210521
Louisville, Kentucky, 40202
Gastroenterology Associates of Central Georgia, LLC /ID# 154857
Macon, Georgia, 31201
Cfagi Llc /Id# 201571
Maitland, Florida, 32751-6108
Duplicate_Clinical Neuroscience Solutions /ID# 164181
Memphis, Tennessee, 38119-4823
Great Lakes Medical Research, LLC /ID# 201732
Mentor, Ohio, 44060-6211
Vista Health Research, LLC /ID# 212664
Miami, Florida, 33176-1032
ITB Research /ID# 161334
Miami, Florida, 33176
Coral Research Clinic /ID# 158549
Miami, Florida, 33186-4643
South Florida Research Ph I-IV, Inc. /ID# 161836
Miami, Florida, 33193
WVU Medicine /ID# 167940
Morgantown, West Virginia, 26506-1200
United Medical Doctors - Murrieta /ID# 158424
Murrieta, California, 92563
Gastroenterology Group Naples /ID# 165206
Naples, Florida, 34102
Vanderbilt University Medical Center /ID# 157138
Nashville, Tennessee, 37232-0011
Digestive Disease Care /ID# 209619
New Hyde Park, New York, 11040
North Shore University Hospital /ID# 168736
New Hyde Park, New York, 11040
Delricht Research /ID# 206542
New Orleans, Louisiana, 70115
Nola Research Works, LLC /ID# 161330
New Orleans, Louisiana, 70115
Advanced Research Institute, Inc /ID# 161959
New Port Richey, Florida, 34653
NYU Langone Medical Center /ID# 160171
New York, New York, 10016-6402
Columbia Univ Medical Center /ID# 161911
New York, New York, 10032-3725
Lenox Hill Hospital /ID# 168465
New York, New York, 10075
DiGiovanna Institute for Medical Education & Research /ID# 171118
North Massapequa, New York, 11758
Southwest Gastroenterology /ID# 165002
Oak Lawn, Illinois, 60453
Advanced Research Institute /ID# 154914
Ogden, Utah, 84403
Hightower Clinical /ID# 211938
Oklahoma City, Oklahoma, 73102
Digestive Disease Specialists /ID# 170774
Oklahoma City, Oklahoma, 73112
University of Nebraska Medical Center /ID# 210057
Omaha, Nebraska, 68198-2000
Endoscopic Research, Inc. /ID# 205901
Orlando, Florida, 32803
Omega Research Maitland, LLC /ID# 171081
Orlando, Florida, 32810-2907
IMIC Inc. Medical Research /ID# 154943
Palmetto Bay, Florida, 33157
Phoenix VA Health Care System /ID# 162267
Phoenix, Arizona, 85012
Children's Hospital of Pittsburgh of UPMC /ID# 210920
Pittsburgh, Pennsylvania, 15224-1334
Northwest Gastroenterology Clinic /ID# 158288
Portland, Oregon, 97210
Wake Radiology UNC REX Healthcare - Raleigh Office /ID# 154880
Raleigh, North Carolina, 27612
Rapid City Medical Center - GI Research /ID# 163841
Rapid City, South Dakota, 57701
McGuire DV AMC /ID# 159990
Richmond, Virginia, 23249
Southern CA Research Ctr., Inc /ID# 167875
Riverside, California, 92501
Mayo Clinic - Rochester /ID# 163085
Rochester, Minnesota, 55905-0001
Clinical Associates in Research Therapeutics of America, LLC /ID# 161336
San Antonio, Texas, 78212
Southern Star Research Institute, LLC /ID# 168770
San Antonio, Texas, 78229-5390
University of California, San Francisco /ID# 157143
San Francisco, California, 94158
HonorHealth Research Institute - Shea /ID# 161783
Scottsdale, Arizona, 85258
Virginia Mason - Seattle Orthapedics /ID# 155545
Seattle, Washington, 98101
Louisana Research Center, LLC /ID# 162236
Shreveport, Louisiana, 71105-6800
St. Louis University /ID# 161902
St Louis, Missouri, 63104
Clinical Research Trials of Florida, Inc. /ID# 201014
Tampa, Florida, 33607
Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211883
Tempe, Arizona, 85284-2604
Cotton-O'Neil Clinical Res Ctr /ID# 154738
Topeka, Kansas, 66606
Center for Digestive Health /ID# 154690
Troy, Michigan, 48098-6363
University of Arizona /ID# 158469
Tucson, Arizona, 85724
Adult Gastroenterology Associates - Gen 1 Research /ID# 206125
Tulsa, Oklahoma, 74136-7823
Tyler Research Institute, LLC /ID# 166796
Tyler, Texas, 75701-4464
Gastro Health & Nutrition - Victoria /ID# 164296
Victoria, Texas, 77904
Cedars-Sinai Medical Center-West Hollywood /ID# 163842
West Hollywood, California, 90048
Velocity Clinical Research - Salt Lake City /ID# 161781
West Jordan, Utah, 84088
Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 161328
Wyoming, Michigan, 49519
Digestive Disease Associates, LTD /ID# 208847
Wyomissing, Pennsylvania, 19610-2002
Japan45 sites
Tokatsu Tsujinaka Hospital /ID# 163362
Abiko-shi, Chiba, 270-1168
Tokyo Medical And Dental University, Medical Hospital /ID# 160157
Bunkyo-ku, Tokyo, 113-8519
Chiba University Hospital /ID# 217532
Chiba, Chiba, 260-8677
Fukuoka University Hospital /ID# 217792
Fukuoka, Fukuoka, 814-0180
NHO Fukuyama Medical Center /ID# 163578
Fukuyama-shi, Hiroshima, 720-8520
Duplicate_Tokai University Hachioji Hospital /ID# 160160
Hachioji-shi, Tokyo, 192-0032
Hamamatsu University Hospital /ID# 205689
Hamamatsu, Shizuoka, 431-3192
National Hospital Organization Mito Medical Center /ID# 160154
Higashi Ibaraki-gun, Ibaraki, 311-3193
Hiroshima University Hospital /ID# 160139
Hiroshima, Hiroshima, 734-8551
Gokeikai Ofuna Chuo Hospital /ID# 171070
Kamakura-shi, Kanagawa, 247-0056
Kanazawa University Hospital /ID# 201766
Kanazawa, Ishikawa-ken, 920-8641
Tsujinaka Hospital Kashiwanoha /ID# 213847
Kashiwa-shi, Chiba, 277-0871
The Jikei University Kashiwa Hospital /ID# 200007
Kashiwa-shi, Chiba, 277-8567
Saitama Medical Center /ID# 160155
Kawagoe-shi, Saitama, 350-8550
Yamanashi Prefectural Central Hospital /ID# 160156
Kofu, Yamanashi, 400-8506
Kurume University Hospital /ID# 160138
Kurume-shi, Fukuoka, 830-0011
Asahikawa Medical University Hospital /ID# 162844
Midorigaokahiga-shi, Hokkaido, 078-8510
The Jikei University Hospital /ID# 163190
Minato-ku, Tokyo, 105-8471
Duplicate_Kitasato University Kitasato Institute Hospital /ID# 160144
Minato-ku, Tokyo, 108-8642
Kyorin University Hospital /ID# 160149
Mitaka-shi, Tokyo, 181-8611
Aichi Medical University Hospital /ID# 160159
Nagakute-shi, Aichi-ken, 480-1195
Daido Clinic /ID# 211477
Nagoya, Aichi-ken, 457-0818
Nagoya University Hospital /ID# 160150
Nagoya, Aichi-ken, 4668560
Nagoya City University Hospital /ID# 160162
Nagoya, Aichi-ken, 467-8602
Nishinomiya Munic Central Hospital /ID# 210104
Nishinomiya-shi, Hyōgo, 663-8014
Hyogo College of Medicine College Hospital /Id# 160164
Nishinomiya-shi, Hyōgo, 663-8501
Osaka City University Hospital /ID# 160146
Osaka, Osaka, 545-8586
Shiga University of Medical Science Hospital /ID# 164022
Ōtsu, Shiga, 520-2192
Kitasato University Hospital /ID# 171071
Sagamihara-shi, Kanagawa, 252-0375
Tokitokai Tokito clinic /ID# 160145
Saitama-shi, Saitama, 336-0963
Toho University Sakura Medical Center /ID# 160161
Sakura-shi, Chiba, 285-8741
Sapporo Tokushukai Hospital /ID# 213493
Sapporo, Hokkaido, 004-0041
Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 160158
Sapporo, Hokkaido, 060-0033
Sapporo Medical University Hospital /ID# 163028
Sapporo, Hokkaido, 060-8543
Tohoku University Hospital /ID# 162843
Sendai, Miyagi, 9808574
Duplicate_Tohoku Rosai Hospital /ID# 163189
Sendai, Miyagi, 981-8563
Tokyo Women's Medical University Hospital /ID# 205973
Shinjuku-ku, Tokyo, 162-8666
NHO Shizuoka Medical Center /ID# 163029
Sunto-gun, Shizuoka, 411-8611
Fujita Health University Hospital /ID# 163214
Toyoake-shi, Aichi-ken, 470-1192
Mie University Hospital /ID# 203639
Tsu, Mie-ken, 514-8507
Wakayama Medical University Hospital /ID# 200183
Wakayama, Wakayama, 641-8510
Yamagata University Hospital /ID# 200154
Yamagata, Yamagata, 990-9585
Yokkaichi Hazu Medical Center /ID# 163741
Yokkaichi-shi, Mie-ken, 510-0016
Yokohama City University Medical Center /ID# 163906
Yokohama, Kanagawa, 232-0024
Yokohama Municipal Citizen's Hospital /ID# 204126
Yokohama, Kanagawa, 240-8555
Germany31 sites
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 212219
Berlin, 10117
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 212893
Berlin, 10117
Gastroenterologische Spezialpraxis am Wittenbergplatz /ID# 211972
Berlin, 10787
MVZ fuer Gastroenterlogie am Bayerischen Platz /ID# 159322
Berlin, 10825
DRK Kliniken Berlin Westend /ID# 166146
Berlin, 14050
Krankenhaus Waldfriede /ID# 212728
Berlin-Zehlendorf, 14163
Stadtisches Klinikum Braunschweig /ID# 163666
Braunschweig, 38126
Universitaetsklinikum Koeln /ID# 164985
Cologne, North Rhine-Westphalia, 50937
Evangelisches Krankenhaus Kalk /ID# 212725
Cologne, North Rhine-Westphalia, 51103
Medizinisches Versorgunszentrum Dachau /ID# 211557
Dachau, 85221
Universitaetsklinikum Erlangen /ID# 159315
Erlangen, Bavaria, 91054
Universitaetsklinikum Frankfurt /ID# 212978
Frankfurt am Main, Hesse, 60590
Agaplesion Markus Krankenhaus /ID# 159317
Frankfurt am Main, 60431
Universitaetsklinikum Freiburg /ID# 162019
Freiburg im Breisgau, Baden-Wurttemberg, 79106
Praxiszentrum fuer Gastroenterologie /ID# 211964
Grevenbroich, North Rhine-Westphalia, 41515
Asklepios Westklinikum Hamburg /ID# 159319
Hamburg, 22559
Medizinische Hochschule Hannover /ID# 162021
Hanover, 30625
Praxis fuer Gastroenterologie /ID# 166145
Heidelberg, Baden-Wurttemberg, 69121
Universitaetsklinikum Jena /ID# 159323
Jena, Thuringia, 07747
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 159321
Kiel, Schleswig-Holstein, 24105
EUGASTRO GmbH /ID# 212076
Leipzig, 04103
Klinikum Lueneburg /ID# 163664
Lüneburg, 21339
Universitaetsklinikum Magdeburg /ID# 211847
Magdeburg, 39120
Universitatsklinikum Mannheim /ID# 162020
Mannheim, Baden-Wurttemberg, 68167
Gastroenterologische Gemeinschaftspraxis Minden /ID# 162018
Minden, 32423
Universitaetsklinikum Muenster /ID# 159316
Münster, North Rhine-Westphalia, 48149
Universitaetsklinikum Regensburg /ID# 163665
Regensburg, 93042
Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 210529
Saarbrücken, Saarland, 66111
Universitaetsklinikum Tuebingen /ID# 159324
Tübingen, Baden-Wurttemberg, 72076
Universitaetsklinikum Ulm /ID# 164986
Ulm, Baden-Wurttemberg, 89081
Duplicate_Gastro-Praxis Wiesbaden /ID# 159318
Wiesbaden, 65189
Canada19 sites
University of Calgary - Heritage Medical Research Clinic /ID# 157152
Calgary, Alberta, T2N 4Z6
Allen Whey Khye Lim Professional Corporation /ID# 169761
Edmonton, Alberta, T5R 1W2
University of Alberta - Zeidler Ledcor Centre /ID# 157098
Edmonton, Alberta, T6G 2X8
Covenant Health /ID# 161617
Edmonton, Alberta, T6K 4B2
Medicor Research Inc /ID# 157149
Greater Sudbury, Ontario, P3A 1W8
CISSS de la Monteregie /ID# 161615
Greenfield Park, Quebec, J4V 2H1
QEII - Health Sciences Centre /ID# 157087
Halifax, Nova Scotia, B3H 2Y9
IWK Health Center /ID# 165900
Halifax, Nova Scotia, B3K 6R8
CHAU- Hotel-Dieu de Levis /ID# 214375
Lévis, Quebec, G6V 3Z1
London Health Sciences Center /ID# 157160
London, Ontario, N6A 5W9
CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 159054
Montreal, Quebec, H1T 2M4
CHUM - Centre hospitalier de l'Universite de Montréal /ID# 167066
Montreal, Quebec, H2X 3E4
Montreal General Hospital - McGill University Health Center /ID# 157084
Montreal, Quebec, H3G 1A4
Fraser Clinical Trials Inc /ID# 159053
New Westminster, British Columbia, V3L 3W4
Scott Shulman Medicine Professional Corporation /ID# 165903
North Bay, Ontario, P1B 2H3
Mount Sinai Hospital /ID# 169762
Toronto, Ontario, M5G 1X5
GIRI Gastrointestinal Research Institute /ID# 157095
Vancouver, British Columbia, V6Z 2K5
Toronto Digestive Disease Asso /ID# 157157
Vaughan, Ontario, L4L 4Y7
Percuro Clinical Research, Ltd /ID# 161616
Victoria, British Columbia, V8V 3M9
Italy18 sites
A.O.U. di Bologna Policlinico S.Orsola-Malpighi /ID# 155635
Bologna, 40138
A.O. Per L'Emergenza Cannizzaro /ID# 161306
Catania, 95126
University of Catanzaro /ID# 212012
Catanzaro, Calabria, 88100
Duplicate_Azienda Ospedaliera Univ. Meyer /ID# 168051
Florence, Tuscany, 50139
Ospedale Policlinico San Martino /ID# 162430
Genova, 16132
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 155633
Milan, 20122
ASST Fatebenefratelli Sacco-Ospedale Sacco /ID# 155631
Milan, 20157
Duplicate_Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 212019
Modena, Emilia-Romagna, 41124
IRCCS Ospedale Sacro Cuore Don Calabria /ID# 161305
Negrar, Verona, 37024
A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 155637
Palermo, 90146
Duplicate_Fondazione IRCCS Policlinico San Matteo /ID# 212029
Pavia, 27100
Policlinico Universitario Campus Bio-Medico /ID# 162429
Rome, Lazio, 00128
Azienda Ospedaliera San Camillo Forlanini /ID# 155636
Rome, Lazio, 00152
Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 166911
Rome, Lazio, 00161
Fondazione PTV Policlinico Tor Vergata /ID# 158021
Rome, Roma, 00133
Presidio Columbus-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Un /ID# 155632
Rome, Roma, 00168
Istituto Clinico Humanitas /ID# 155634
Rozzano, Milano, 20089
Duplicate_AOU Ospendali Riuniti di Ancona /ID# 162427
Torrette, Ancona, 60123
China16 sites
The Second Hospital Central South University /ID# 211696
Changsha, 410011
West China Hospital, Sichuan University /ID# 210889
Chengdu, 610041
Guangdong Provincial People's Hospital /ID# 212948
Guangzhou, Guangdong, 510080
The Sixth Affiliated Hosp Sun /ID# 210785
Guangzhou, Guangdong, 510655
The second Affiliated hospital of Zhejiang University school of Medicine /ID# 210725
Hangzhou, Zhejiang, 310009
Sir Run Run Shaw Hospital Zhejiang University School of Medicine /ID# 210624
Hangzhou, Zhejiang, 310020
Jinhua Municipal Central Hospital /ID# 215626
Jinhua, Zhejiang, 321000
The First Affiliated Hospital of Nanchang University /ID# 211034
Nanchang, Jiangxi, 330006
Shanghai East Hospital /ID# 212683
Pudong New District, 200136
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 210841
Shanghai, Shanghai Municipality, 200065
Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 210707
Shanghai, Shanghai Municipality, 200127
The Second Hospital of Hebei Medical University /ID# 212740
Shijiazhuang, Hebei, 050000
Tianjin Medical University General Hospital /ID# 210927
Tianjin, 300052
Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 210856
Wuhan, Hubei, 430022
Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 211038
Wuhan, Hubei, 430022
Renmin Hospital of Wuhan University /ID# 214873
Wuhan, Hubei, 430060
Poland15 sites
Centrum Medyczne LukaMed Joanna Luka-Wendrowska /ID# 212081
Chojnice, Pomeranian Voivodeship, 89-600
Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego w Lodzi /ID# 212297
Lodz, Łódź Voivodeship, 90-153
1 Wojskowy Szpital Kliniczny Z Poliklinika /Id# 209985
Lublin, Lublin Voivodeship, 20-049
Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie /ID# 209981
Lublin, Lublin Voivodeship, 20-954
Wojewodzki Szpital Specjalistyczny /ID# 212402
Olsztyn, Warmian-Masurian Voivodeship, 10-561
Duplicate_SOLUMED Sp. z o.o., Sp.k. /ID# 160793
Poznan, 60-529
Centrum Medyczne Medyk /ID# 212889
Rzeszów, Podkarpackie Voivodeship, 35-326
Gastromed /Id# 212099
Torun, Kuyavian-Pomeranian Voivodeship, 87-100
H-T. Centrum Medyczne - Endoterapia /ID# 212459
Tychy, Silesian Voivodeship, 43-100
Centrum Zdrowia MDM /ID# 160794
Warsaw, Masovian Voivodeship, 00-635
Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 160797
Warsaw, Masovian Voivodeship, 02-507
Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 213579
Warsaw, Masovian Voivodeship, 04-730
Duplicate_Niepubliczny Zakład Opieki Zdrowotnej VIVAMED Jadwiga Miecz /ID# 205160
Warsaw, 03-580
Planetmed Sp. z o.o. /ID# 202798
Wroclaw, Lower Silesian Voivodeship, 52-210
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclaw /ID# 212602
Wroclaw, 50-556
United Kingdom13 sites
Cambridge University Hospitals NHS Foundation Trust /ID# 158031
Cambridge, CB2 0QQ
Ashford and St Peter's Hospitals NHS Foundation Trust /ID# 207937
Chertsey, Surrey, KT16 0PZ
NHS Lothian /ID# 207447
Edinburgh, EH3 9HE
Royal Devon and Exeter NHS Trust Hospital /ID# 157517
Exeter, Devon, EX2 5DW
Calderdale and Huddersfield NHS Foundation Trust /ID# 209569
Huddersfield, HX3 0PW
Hull University Teaching Hospitals NHS Trust /ID# 158757
Hull, HU3 2JZ
Leeds Teaching Hospitals NHS Trust /ID# 157523
Leeds, LS9 7TF
Barts Health NHS Trust /ID# 163710
London, London, City of, E1 2ES
Guy's and St Thomas' NHS Foundation Trust /ID# 157519
London, London, City of, SE1 9RT
Duplicate_King's College Hospital NHS Foundation Trusts /ID# 158756
London, SE5 9RS
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 163709
Newcastle upon Tyne, NE7 7DN
Oxford University Hospitals NHS Foundation Trust /ID# 158033
Oxford, OX3 9DU
Duplicate_Northern Care Alliance NHS Group /ID# 207764
Salford, M6 8HD
Spain12 sites
Hospital Clinic de Barcelona /ID# 157526
Barcelona, 08036
Hospital Universitario Basurto /ID# 205189
Bilbao, Vizcaya, 48013
Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 157527
Ferrol, A Coruna, 15405
Hospital General Universitario Gregorio Maranon /ID# 161435
Madrid, 28007
Hospital Universitario La Paz /ID# 159228
Madrid, 28046
Hospital Universitario Puerta de Hierro, Majadahonda /ID# 157575
Majadahonda, Madrid, 28222
Consorci Corporacio Sanitaria Parc Tauli Sabadell /ID# 159230
Sabadell, Barcelona, 08208
Hospital Clinico Universitario de Salamanca /ID# 157532
Salamanca, 37007
Hospital Universitario Virgen Macarena /ID# 160819
Seville, 41009
Hospital Universitario y Politecnico La Fe /ID# 157530
Valencia, 46026
Hospital Clinico Universitario Lozano Blesa /ID# 212523
Zaragoza, 50009
Hospital Universitario Miguel Servet /ID# 157531
Zaragoza, 50009
Ukraine12 sites
Kharkiv City Clinical Hospital No.2 n.a. Prof. O.O. Shalimov /ID# 165649
Kharkiv, 61037
Municipal Nonprofit Enterprise Kherson city clinical hospital n.a. Y.Y. Karabel /ID# 212050
Kherson, 73000
Kyiv Municipal Clinical Hospital #18 /ID# 162521
Kyiv, 01030
International Institute of Clinical Research LLC /ID# 211997
Kyiv, 02091
Communal Noncommercial Institution Consultative and Diagnostic Center of Desnian /ID# 165651
Kyiv, 02232
Medical Center of LLC Medbud-Clinic /ID# 216929
Kyiv, 03037
Kyiv Railway Clinical Hosp No.2 /ID# 217330
Kyiv, 03049
Communal Enterprise Volyn Regional Clinical hospital of the Volyn Regional Coun /ID# 206788
Lutsk, 43005
Lviv Railway Clinical Hospital of branch Healthcare Centers of Public Joint Stoc /ID# 165650
Lviv, 79000
Duplicate_Transcarpathian Regional Clin. /ID# 168419
Uzhhorod, 88000
Scientific Research Institute of Invalid Rehabilitation /ID# 211516
Vinnytsia, Vinnytsia Oblast, 21029
MNPE Vinnytsia Regional Clinical Hospital n.a. M.I. Pyrohov /ID# 216265
Vinnytsia, 21018
Portugal11 sites
Hospital Garcia de Orta, EPE /ID# 160747
Almada, 2805-267
Centro Hospitalar Universitário do Algarve, EPE - Hospital Faro /ID# 160715
Faro, 8000-386
Hospital da Senhora da Oliveira Guimaraes, EPE /ID# 160739
Guimarães, Braga District, 4835-044
Centro Hospitalar Universitario Lisboa Central, EPE - Hospital dos Capuchos /ID# 160675
Lisbon, 1169-050
Centro Hospitalar de Lisboa Ocidental, EPE - Hospital Egas Moniz /ID# 167749
Lisbon, 1349-019
Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 160694
Lisbon, 1649-035
Hospital Beatriz Ângelo /ID# 207757
Loures, 2674-514
Centro Hospitalar Universitário do Algarve, EPE - Hospital de Portimão /ID# 167750
Portimão, Faro District, 8500-338
Centro Hospitalar Universitario de Sao Joao, EPE /ID# 160695
Porto, 4200-319
Centro Hospitalar de Entre Douro e Vouga /ID# 160674
Santa Maria DA Feira, Porto District, 4520-211
Centro Hosp de Tondela-Viseu /ID# 160697
Viseu, 3504-509
Russia11 sites
Alliance Biomedical Ural Group /ID# 156950
Izhevsk, Udmurtiya Republic, 426061
Kuzbass Regional Clinical Hospital /ID# 161310
Kemerovo, Kemerovo Oblast, 650099
State Scientific Ctr Coloproct /ID# 204809
Moscow, 123423
Novosibirski Gastrocenter /ID# 217554
Novosibirsk, 630007
Duplicate_Perm state medical university n.a. E.A. Vagner /ID# 207440
Perm, Permskiy Kray, 614990
Duplicate_St. Petersburg State Pediatric Medical University /ID# 211977
Saint Petersburg, Sankt-Peterburg, 194100
City Clinical Hospital No. 31 /ID# 208866
Saint Petersburg, 197110
Professor Pasechnikov Gastroenterology and Pankreatology clinic /ID# 156949
Stavropol, Stavropol Kray, 355012
Tver Regional Clinical Hospital /ID# 205925
Tver', Tver Oblast, 170036
Regional Clinical Hospital #1 /ID# 163453
Tyumen, Tyumen Oblast, 625023
Duplicate_Ulyanovsk State clinical hospi /ID# 156946
Ulyanovsk, 432063
South Korea11 sites
Dong-A University Hospital /ID# 158675
Busan, 49201
Pusan National University Hospital /ID# 158677
Busan, 49241
Yeungnam University Medical Center /ID# 158680
Daegu, 42415
The Catholic University of Korea, Daejeon St.Mary's Hospital /ID# 213552
Daejeon, 34943
Hanyang University Guri Hospital /ID# 158673
Guri-si, Gyeonggido, 11923
Duplicate_CHA bundang medical center CHA University /ID# 158672
Seongnam-si, Gyeonggido, 13496
Kangbuk Samsung Hospital /ID# 158676
Seoul, Seoul Teugbyeolsi, 03181
Severance Hospital /ID# 158671
Seoul, Seoul Teugbyeolsi, 03722
Asan Medical Center /ID# 158678
Seoul, 05505
Samsung Medical Center /ID# 158674
Seoul, 06351
Duplicate_The Catholic University of Korea, ST. Vincent's Hospital /ID# 158681
Suwon, Gyeonggido, 16247
Belgium9 sites
Imelda Ziekenhuis /ID# 157392
Bonheiden, 2820
ULB Hospital Erasme /ID# 157397
Brussels, Brussels Capital, 1070
UZ Gent /ID# 157394
Ghent, Oost-Vlaanderen, 9000
CHU UCL Namur - site Godinne /ID# 157401
Godinne, Namur, 5530
Universitair Ziekenhuis Leuven /ID# 157396
Leuven, Vlaams-Brabant, 3000
CHU de Liege /ID# 157398
Liège, 4000
Groupe Sante CHC - Clinique du MontLegia /ID# 157393
Liège, 4000
AZ-Delta /ID# 157391
Roeselare, 8800
UCL Saint-Luc /ID# 157395
Woluwe-Saint-Lambert, Brussels Capital, 1200
Czechia9 sites
Hepato-Gastroenterologie HK, s.r.o. /ID# 163134
Hradec Králové, 500 12
CTCenter MaVe s.r.o. /ID# 163149
Olomouc, 779 00
Nemocnice Pardubickeho kraje, a.s. /ID# 163182
Pardubice, 530 03
Duplicate_Institut klinicke a experimentalni mediciny (IKEM) /ID# 165463
Prague, Praha 4, 140 00
Nemocnice Milosrdnych sester sv. Karla Boromejskeho v Praze /ID# 211305
Prague, 118 33
Axon Clinical, s.r.o. /ID# 163176
Prague, 140 00
Thomayerova nemocnice /ID# 162940
Prague, 140 59
ResTrial s.r.o. /ID# 211075
Prague, 143 00
NH Hospital a.s. /ID# 211076
Prague, 155 00
Israel9 sites
Soroka University Medical Center /ID# 157798
Beersheba, Southern District, 8443901
Duplicate_Rambam Medical Center /ID# 171072
Haifa, 3109601
The Edith Wolfson Medical Center /ID# 217329
Holon, 5822000
Shaare Zedek Medical Center /ID# 163540
Jerusalem, 91031
Shaare Zedek Medical Center /ID# 171073
Jerusalem, 91031
Hadassah Medical Center-Hebrew University /ID# 165913
Jerusalem, 91120
Sheba Medical Center /ID# 157797
Ramat Gan, Tel Aviv, 5239424
Sheba Medical Center /ID# 171074
Ramat Gan, Tel Aviv, 5239424
Tel Aviv Sourasky Medical Center /ID# 157796
Tel Aviv, Tel Aviv, 6423906
Serbia9 sites
Clinical Hosp Center Zvezdara /ID# 156978
Belgrade, Beograd, 11000
Military Medical Academy /ID# 156979
Belgrade, Beograd, 11000
University Clinical Center Serbia /ID# 156973
Belgrade, Beograd, 11000
Clin Hosp Ctr Bezanijska Kosa /ID# 156976
Belgrade, Beograd, 11080
University Children's Hospital 'Tirsova' /ID# 211481
Belgrade, 11000
Clinical Hospital Center Dr Dragisa Misovic - Dedinje /ID# 212797
Belgrade, 11040
University Clinical Center Kragujevac /ID# 156975
Kragujevac, Sumadijski Okrug, 34000
General Hospital Leskovac /ID# 209574
Leskovac, 16000
Clinical Center Vojvodina /ID# 156972
Novi Sad, Vojvodina, 21000
Bulgaria8 sites
UMHAT Dr Georgi Stranski EAD /ID# 203977
Pleven, 5800
University Multiprofile Hospit /ID# 158644
Plovdiv, 4001
Second Multiprofile Hospital f /ID# 158646
Sofia, 1202
Duplicate_Tokuda Hospital Sofia /ID# 158645
Sofia, 1407
UMHAT Sveti Ivan Rilski /ID# 204714
Sofia, 1431
UMHAT Tsaritsa Joanna - ISUL /ID# 211240
Sofia, 1527
MHAT Trakia /ID# 201672
Stara Zagora, 6004
University Multiprofile Hospit /ID# 167575
Varna, 9010
Brazil7 sites
Upeclin Fmb - Unesp /Id# 157688
Botucatu, São Paulo, 18618-686
Hospital Nossa Senhora das Graças /ID# 157646
Curitiba, Paraná, 80810-040
Instituto Goiano de Gastroenterologia e Endoscopia Digestiva /ID# 157672
Goiânia, Goiás, 74535-170
Hospital de Clinicas de Porto Alegre /ID# 157653
Porto Alegre, Rio Grande do Sul, 90035-903
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP /ID# 157649
Ribeirão Preto, São Paulo, 14051-140
Faculdade de Medicina do ABC /ID# 159672
Santo André, São Paulo, 09060-870
Kaiser Clinica e Hospital Dia /ID# 157656
São José do Rio Preto, São Paulo, 15015-110
Greece7 sites
General Hospital of Chest Diseases of Athens SOTIRIA /ID# 171077
Athens, Attica, 11527
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 157428
Athens, 10676
University General Hospital of Heraklion PA.G.N.I /ID# 157427
Heraklion, Crete, 71307
University General Hospital of Ioannina /ID# 157425
Ioannina, 45500
Tzaneio general hospital of Piraeus /ID# 206445
Piraeus, Attica, 18536
General Hospital of Nikaia-Piraeus "Agios Panteleimon"- general hospital dytikis /ID# 157429
Pireaus, 18454
Theageneio Anticancer Hospital /ID# 163921
Thessaloniki, 54639
Sweden7 sites
Sahlgrenska University Hospital /ID# 157879
Gothenburg, Västra Götaland County, 413 45
Skane University hospital /ID# 211235
Malmö, Skåne County, 214 28
Duplicate_SU Molndal. /ID# 157880
Mölndal, 431 80
Duplicate_Karolinska Univ Sjukhuset /ID# 209966
Solna, 171 64
Duplicate_GHP Stockholm Gastro Center /ID# 210479
Stockholm, Stockholm County, 114 28
Ersta diakoni /ID# 157878
Stockholm, Stockholm County, 116 91
Danderyd Hospital /ID# 202136
Stockholm, Stockholm County, 182 88
Australia5 sites
Emeritus Research /ID# 213511
Camberwell, Victoria, 3124
Lyell McEwin Hospital /ID# 211363
Elizabeth Vale, South Australia, 5112
Footscray Hospital /ID# 211361
Footscray, Victoria, 3011
Duplicate_Mater Hospital /ID# 167990
South Brisbane, Queensland, 4101
Griffith University /ID# 212627
Southport, Queensland, 4222
Croatia5 sites
UHC Osijek /ID# 157564
Osijek, County of Osijek-Baranja, 31000
Klinicki bolnicki centar Split /ID# 157567
Split, Split-Dalmatia County, 21000
Duplicate_Klinicka bolnica Dubrava Zagreb /ID# 157565
Zagreb, City of Zagreb, 10000
Klinicki bolnicki centar Sestre milosrdnice /ID# 157721
Zagreb, City of Zagreb, 10000
Klinicki bolnicki centar Zagreb /ID# 157566
Zagreb, City of Zagreb, 10000
Romania5 sites
Tvm Med Serv Srl /Id# 166294
Cluj-Napoca, 400132
Institutul Clinic Fundeni /ID# 163046
Sector 2, Bucharest, 022328
Institutul Clinic Fundeni /ID# 163264
Sector 2, Bucharest, 022328
Cabinet Particular Policlinic Algomed /ID# 163047
Timișoara, 300002
Duplicate_Centrul Medical Tuculanu SRL /ID# 166295
Timișoara, 300168
South Africa5 sites
Kingsbury Hospital /ID# 163116
Cape Town, Western Cape, 7708
Private Practice Dr MN Rajabally /ID# 163115
Cape Town, Western Cape, 7800
Spoke Research Inc /ID# 158117
CAPE TOWN Milnerton, Western Cape, 7441
Clinresco Centers /ID# 163864
Johannesburg, Gauteng, 1619
Wits Clinical Research Site /ID# 158115
Johannesburg, Gauteng, 2193
Austria4 sites
Medizinische Universitaet Graz /ID# 158137
Graz, Styria, 8036
Universitaetsklinikum St. Poelten /ID# 166425
Sankt Pölten, Lower Austria, 3100
Krankenhaus der Barmherzigen Brueder Wien /ID# 212059
Vienna, State of Vienna, 1020
Duplicate_Medical University of Vienna /ID# 158138
Vienna, State of Vienna, 1090
Chile4 sites
Hospital Guillermo Grant Benavente de Concepción /ID# 210759
Concepción, 4070038
Complejo Asistencial Dr. Sotero del Rio /ID# 169382
Santiago, Santiago Metropolitan, 8207257
Hospital Las Higueras /ID# 167090
Talcahuano, 1740000
Centro de Investigaciones Clínicas Viña del Mar /ID# 203589
Viña del Mar, Valparaiso, 2540488
Colombia4 sites
Hospital Univ San Ignacio /ID# 158733
Bogota, Cundinamarca, 110231
Instituto de Coloproctologia /ID# 158741
Medellín, Antioquia, 050024
Hospital Pablo Tobon Uribe /ID# 158735
Medellín, Antioquia, 50034
Hospital Universitario San Vic /ID# 171487
Medellín, 50010
Mexico4 sites
JM Research SC /ID# 161733
Cuernavaca, Morelos, 62290
Health Pharma Professional Research S.A de C.V /ID# 161734
Del. Benito Juárez, 03810
Unidad de Atencion Medica e Investigacion en Salud /ID# 163624
Mérida, Yucatán, 97000
Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de C.V. /ID# 167648
Zapopan, Jalisco, 45070
Norway4 sites
Helse More og Romsdal HF, Alesund sjukehus /ID# 212811
Ålesund, 6017
Vestre viken - Baerum Sykehus /ID# 157886
Gjettum, 1346
Sykehuset Levanger Helse NT /ID# 157885
Levanger, 7601
Akershus universitetssykehus /ID# 169378
Nordbyhagen, Akershus, 1474
Slovakia4 sites
Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 156465
Banská Bystrica, 975 17
Univerzitna nemocnica Martin /ID# 163200
Martin, 036 01
KM Management, spol. s.r.o. /ID# 206763
Nitra, 949 01
GASTRO I., s.r.o. /ID# 156466
Prešov, 080 01
Belarus3 sites
Grodno city clinical hospital #2 /ID# 159499
Grodno, 230011
Gomel Regional Clinical Hospital /ID# 159498
Homyel, 246029
Vitebsk Regional Advanced Clin /ID# 159497
Vitebsk, 210001
Bosnia and Herzegovina3 sites
University Clinical Centre of the Republic of Srpska /ID# 157717
Banja Luka, Republika Srpska, 78000
University Clinical Centre of the Republic of Srpska /ID# 164512
Banja Luka, Republika Srpska, 78000
Clinical Center University of Sarajevo /ID# 165134
Sarajevo, 71000
Estonia3 sites
East Tallinn Central Hospital /ID# 157076
Tallinn, Harju, 10138
West Tallinn Central Hospital /ID# 157077
Tallinn, 10617
North Estonia Medical Centre /ID# 163507
Tallinn, 13419
Ireland3 sites
Beaumont Hospital /ID# 157515
Beaumont, Dublin, D09 XR63
St Vincent's University Hospital /ID# 157512
Elm Park, Dublin, D04 T6F4
University Hospital Galway /ID# 157513
Galway, H91 YR71
Latvia3 sites
Pauls Stradins Clinical University Hospital /ID# 159614
Riga, 1002
Digestive Disease Center Gastro /ID# 163105
Riga, LV-1079
Riga East Clinical University Hospital /ID# 159613
Riga, LV-1079
Malaysia3 sites
Queen Elizabeth Hospital /ID# 160654
Division Pantai Barat Utara, Sabah, 88200
Universiti Sains Malaysia /ID# 160656
Kelantan, Kelantan, 16150
Universiti Kebangsaan Malaysia (UKM) Medical Centre /ID# 163654
Kuala Lumpur, Selangor, 56000
New Zealand3 sites
Christchurch Hospital /ID# 163074
Christchurch, Canterbury, 8011
Dunedin Hospital /ID# 167989
Dunedin, Otago, 9016
Wellington Regional Hospital /ID# 167987
Newtown Wellington, Wellington Region, 6021
Singapore3 sites
National University Hospital /ID# 160658
Singapore, 119074
Singapore General Hospital /ID# 160657
Singapore, 169608
KL Ling Gastroenterology and Liver Clinic /ID# 205737
Singapore, 228510
Switzerland3 sites
Duplicate_Universitaetsspital Basel /ID# 164555
Basel, 4031
Inselspital, Universitätsspital Bern /ID# 163531
Bern, 3010
Universitätsspital Zürich /ID# 163532
Zurich, Canton of Zurich, 8091
Argentina2 sites
Hospital Privado Univesitario /ID# 161988
Córdoba, 5016
Duplicate_HOSPITAL CENTENARIO /ID# 170883
Rosario, Santa Fe Province, 2000
Hong Kong2 sites
Queen Mary Hospital /ID# 163902
Hong Kong, 999077
Tuen Mun Hospital /ID# 163901
Tuenmen
Lithuania2 sites
Duplicate_Hospital of lithuanian university of Health Science Kauno Klinikos /ID# 162582
Kaunas, 50161
Duplicate_Vilnius University Hospital /ID# 162507
Vilnius, LT-08661
Netherlands2 sites
Academisch Medisch Centrum /ID# 157950
Amsterdam, 1105 AZ
Elisabeth Tweesteden Ziekenhuis /ID# 163631
Tilburg, 5022 GC
About this study
Official title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
- Conditions
- Crohn's Disease
- Being tested
- placebo for risankizumab, risankizumab IV, risankizumab SC
- Keywords
- Crohn's Disease (CD), Risankizumab, ABBV-066, BI 655066
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placebo for risankizumabDrug
Placebo for risankizumab administered by intravenous infusion
risankizumab IVDrug
Also called ABBV-066 BI 655066, SKYRIZI
Risankizumab administered by intravenous infusion
risankizumab SCDrug
Also called ABBV-066 BI 655066, SKYRIZI
Risankizumab administered by subcutaneous (SC) injection
| Study group | Role | What they receive |
|---|---|---|
| Risankizumab Dose 1 (Period 1) | Experimental | Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion. Receives: Drug: risankizumab IV |
| Risankizumab Dose 2 (Period 1) | Experimental | Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion. Receives: Drug: risankizumab IV |
| Placebo (Period 1) | Placebo comparator | Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion. Receives: Drug: placebo for risankizumab |
| Risankizumab Dose 1 (Period 2) | Experimental | Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2. Receives: Drug: risankizumab IV |
| Risankizumab Dose 2 (Period 2) | Experimental | Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2. Receives: Drug: risankizumab SC |
| Risankizumab Dose 3 (Period 2) | Experimental | Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2. Receives: Drug: risankizumab SC |
What is being measured
The primary outcome is the main question the study is designed to answer.
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
The CDAI consists of 8 components; 7 are based on participant diary entries, participant interviews, physical examinations, measurement of body weight and height and 1 is based on laboratory analysis. CDAI clinical remission of Crohn's disease is defined as CDAI < 150.
Measured: Week 12
US Specific: Percentage of Participants With Endoscopic Response
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).
Measured: Week 12
Global Outside of US: Percentage of Participants With Clinical Remission
Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.
Measured: Week 12
Global Outside of US: Percentage of Participants With Endoscopic Response
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).
Measured: Week 12
Secondary outcomes (31)
US Specific: Percentage of Participants With Clinical Remission
Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.
Measured: Week 12
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
Measured: Week 4
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
Measured: Week 12
US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.
Measured: Week 12
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical remission of Crohn's disease is defined as CDAI < 150.
Measured: Week 4
US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
Endoscopic response was a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) > 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).
Measured: Week 12
US Specific: Percentage of Participants With Stool Frequency (SF) Remission
Stool Frequency (SF) remission is defined as an average daily SF <= 2.8 and not worse than baseline.
Measured: Week 12
US Specific: Percentage of Participants With Abdominal Pain (AP) Remission
The Abdominal Pain rating is an assessment that is graded from 0 to 3: 0= None, 1= Mild, 2= Moderate and 3= Severe. AP remission is defined as average daily AP score <= 1 and not worse than baseline.
Measured: Week 12
US Specific: Percentage of Participants With Endoscopic Remission
Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable
Measured: Week 12
US Specific: Percentage of Participants With Enhanced Clinical Response
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
Measured: Week 4
US Specific: Percentage of Participants With Ulcer-Free Endoscopy
Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline
Measured: Week 12
US Specific: Percentage of Participants With Enhanced Clinical Response
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
Measured: Week 12
US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at
Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.
Measured: Week 12
US Specific: Percentage of Participants With CD-Related Hospitalization
Participants with at least one admission to the hospital due to Crohn's Disease.
Measured: Week 12
US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline
Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.
Measured: Week 12
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. CDAI clinical remission of Crohn's disease is defined as CDAI < 150.
Measured: Week 12
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
Measured: Week 4
Global Outside of US: Percentage of Participants With Clinical Remission
Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.
Measured: Week 4
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
Measured: Week 12
Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.
Measured: Week 12
Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.
Measured: Week 12
Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response
Enhanced clinical response was defined as ≥ 60% decrease in average daily Stool Frequency and/or ≥ 35% decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission. Endoscopic Response was defined as a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) > 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).
Measured: Week 12
Global Outside of US: Percentage of Participants With Endoscopic Remission
Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable
Measured: Week 12
Global Outside of US: Percentage of Participants With Enhanced Clinical Response
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
Measured: Week 4
Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy
Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline
Measured: Week 12
Global Outside of US: Percentage of Participants With Enhanced Clinical Response
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
Measured: Week 12
Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline
Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.
Measured: Week 12
Global Outside of US: Percentage of Participants With CD-Related Hospitalization
Participants with at least one admission to the hospital due to Crohn's Disease.
Measured: Week 12
Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline
Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.
Measured: Week 12
Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment
WPAI: CD is a questionnaire used to evaluate lost productivity due to CD ; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Total work productivity impairment takes into account both hours missed due to CD symptoms and the patient's assessment of the degree to which CD affected their productivity while working (overall work impairment [OWI]). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Measured: Week 12
Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score
The Short Form-36 Health Survey determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.
Measured: Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2017
- Study start10 May 2017
- Primary completion9 Nov 2020
- Study completion14 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Crohn's DiseaseStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 931 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03105128
- Sponsor's protocol ID
- M16-006
- Other IDs
- 2016-003123-32, 2016
- Status last verified
- Jun 2022
- First submitted
- 4 Apr 2017
- Last updated
- 6 Jul 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
- Expanded access
- Available
Publications
Panaccione R, Ferrante M, Dotan I, Panes J, Hisamatsu T, Bossuyt P, Danese S, Song A, Kalabic J, Joshi N, Zambrano J, Zhang Y, Duan WR, Kligys K, Dubinsky MC, Lindsay JO, Vermeire S, Siegmund B, Irving PM, D'Haens G. Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment. Clin Gastroenterol Hepatol. 2025 Oct;23(11):2012-2022.e6. doi: 10.1016/j.cgh.2024.12.023. Epub 2025 Feb 3.
PubMed 39909280Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, Kligys K, Song A, Zambrano J, Mallick M, Zhang Y, Armuzzi A, D'Haens G. Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. J Crohns Colitis. 2025 Apr 4;19(4):jjae164. doi: 10.1093/ecco-jcc/jjae164.
PubMed 39485390Peyrin-Biroulet L, Colombel JF, Louis E, Ferrante M, Motoya S, Panaccione R, Torres J, Ungaro RC, Kligys K, Kalabic J, Zambrano J, Zhang Y, D'Haens G. Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies. Gastro Hep Adv. 2024 Mar 7;3(4):539-550. doi: 10.1016/j.gastha.2024.02.008. eCollection 2024.
PubMed 39131711Louis E, Lee WJ, Litcher-Kelly L, Ollis S, Pranschke E, Fitzgerald K, Lacerda AP, Neimark E, Sanchez Gonzalez Y, Panes J. Content Validity and Psychometric Evaluation of the Crohn's Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn's Disease. Adv Ther. 2024 Sep;41(9):3678-3705. doi: 10.1007/s12325-024-02923-9. Epub 2024 Aug 6.
PubMed 39105965Schreiber S, Cross RK, Panaccione R, D'Haens G, Bossuyt P, Dotan I, Colombel JF, Louis E, Dubinsky MC, Kligys K, Neimark E, Song A, Zambrano J, Kalabic J, Cheng E, Zhang Y, Ferrante M. Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease. Aliment Pharmacol Ther. 2024 Oct;60(7):897-906. doi: 10.1111/apt.18184. Epub 2024 Jul 25.
PubMed 39054592Dubinsky M, Ma C, Griffith J, Crowell M, Neimark E, Kligys K, O'Connell T. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease. Adv Ther. 2023 Sep;40(9):3896-3911. doi: 10.1007/s12325-023-02546-6. Epub 2023 Jun 27.
PubMed 37368103Loftus EV Jr, Ananthakrishnan AN, Lee WJ, Gonzalez YS, Fitzgerald KA, Wallace K, Zhou W, Litcher-Kelly L, Ollis SB, Su S, Danese S. Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative Colitis. Pharmacoecon Open. 2023 Sep;7(5):823-840. doi: 10.1007/s41669-023-00419-w. Epub 2023 Jun 9.
PubMed 37296268D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panes J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6.
PubMed 35644154
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
- ClinicalTrials.gov ID
- NCT03105128
- Acronym / sponsor ID
- M16-006
- Conditions
- Crohn's Disease
- Keywords
- Crohn's Disease (CD), Risankizumab, ABBV-066, BI 655066
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 931 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 10 May 2017 (actual)
- Primary completion
- 9 Nov 2020 (actual)
- Study completion
- 14 Apr 2021 (actual)
- First posted
- 7 Apr 2017 (actual)
- Results
- Posted 6 Jul 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Risankizumab Dose 1 (Period 1) | Experimental | Drug: risankizumab IVParticipants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion. |
| Risankizumab Dose 2 (Period 1) | Experimental | Drug: risankizumab IVParticipants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion. |
| Placebo (Period 1) | Placebo comparator | Drug: placebo for risankizumabParticipants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion. |
| Risankizumab Dose 1 (Period 2) | Experimental | Drug: risankizumab IVParticipants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2. |
| Risankizumab Dose 2 (Period 2) | Experimental | Drug: risankizumab SCParticipants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2. |
| Risankizumab Dose 3 (Period 2) | Experimental | Drug: risankizumab SCParticipants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2. |
Who may qualify
- Ages
- 16 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Male or female aged >=18 to <= 80 years, or minimum age of adult consent according to local regulations, at the Baseline Visit. Where locally permissible, participants 16 to < 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit.
- Diagnosis of CD for at least 3 months prior to Baseline.
- Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD).
- Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD.
- If female, participant must meet the contraception recommendations.
Key exclusion criteria (7 listed)
- Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.
- Participants with unstable doses of concomitant Crohn's disease therapy.
- Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks prior to Baseline), or any investigational biologic or other agent or procedure within 35 days or 5 half-lives prior to Baseline, whichever is longer.
- Prior exposure to p19 inhibitors (e.g., risankizumab).
- Complications of Crohn's disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placebo for risankizumabPlacebo for risankizumab administered by intravenous infusion | Drug | Placebo (Period 1) |
| risankizumab IVAlso: ABBV-066 BI 655066, SKYRIZIRisankizumab administered by intravenous infusion | Drug | Risankizumab Dose 1 (Period 1), Risankizumab Dose 1 (Period 2), Risankizumab Dose 2 (Period 1) |
| risankizumab SCAlso: ABBV-066 BI 655066, SKYRIZIRisankizumab administered by subcutaneous (SC) injection | Drug | Risankizumab Dose 2 (Period 2), Risankizumab Dose 3 (Period 2) |
Primary outcome
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
Time frame: Week 12
The CDAI consists of 8 components; 7 are based on participant diary entries, participant interviews, physical examinations, measurement of body weight and height and 1 is based on laboratory analysis. CDAI clinical remission of Crohn's disease is defined as CDAI < 150.
US Specific: Percentage of Participants With Endoscopic Response
Time frame: Week 12
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).
Global Outside of US: Percentage of Participants With Clinical Remission
Time frame: Week 12
Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.
Global Outside of US: Percentage of Participants With Endoscopic Response
Time frame: Week 12
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).
31 secondary outcomes
US Specific: Percentage of Participants With Clinical Remission
Time frame: Week 12
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Time frame: Week 4
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Time frame: Week 12
US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
Time frame: Week 12
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
Time frame: Week 4
US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response
Time frame: Week 12
US Specific: Percentage of Participants With Stool Frequency (SF) Remission
Time frame: Week 12
US Specific: Percentage of Participants With Abdominal Pain (AP) Remission
Time frame: Week 12
US Specific: Percentage of Participants With Endoscopic Remission
Time frame: Week 12
US Specific: Percentage of Participants With Enhanced Clinical Response
Time frame: Week 4
US Specific: Percentage of Participants With Ulcer-Free Endoscopy
Time frame: Week 12
US Specific: Percentage of Participants With Enhanced Clinical Response
Time frame: Week 12
US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at
Time frame: Week 12
US Specific: Percentage of Participants With CD-Related Hospitalization
Time frame: Week 12
US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline
Time frame: Week 12
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
Time frame: Week 12
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Time frame: Week 4
Global Outside of US: Percentage of Participants With Clinical Remission
Time frame: Week 4
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Time frame: Week 12
Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
Time frame: Week 12
Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
Time frame: Week 12
Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response
Time frame: Week 12
Global Outside of US: Percentage of Participants With Endoscopic Remission
Time frame: Week 12
Global Outside of US: Percentage of Participants With Enhanced Clinical Response
Time frame: Week 4
Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy
Time frame: Week 12
Global Outside of US: Percentage of Participants With Enhanced Clinical Response
Time frame: Week 12
Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline
Time frame: Week 12
Global Outside of US: Percentage of Participants With CD-Related Hospitalization
Time frame: Week 12
Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline
Time frame: Week 12
Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment
Time frame: Week 12
Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score
Time frame: Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 39909280Panaccione R, Ferrante M, Dotan I, Panes J, Hisamatsu T, Bossuyt P, Danese S, Song A, Kalabic J, Joshi N, Zambrano J, Zhang Y, Duan WR, Kligys K, Dubinsky MC, Lindsay JO, Vermeire S, Siegmund B, Irving PM, D'Haens G. Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment. Clin Gastroenterol Hepatol. 2025 Oct;23(11):2012-2022.e6. doi: 10.1016/j.cgh.2024.12.023. Epub 2025 Feb 3.
- Derived from this study: PubMed 39485390Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, Kligys K, Song A, Zambrano J, Mallick M, Zhang Y, Armuzzi A, D'Haens G. Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. J Crohns Colitis. 2025 Apr 4;19(4):jjae164. doi: 10.1093/ecco-jcc/jjae164.
- Derived from this study: PubMed 39131711Peyrin-Biroulet L, Colombel JF, Louis E, Ferrante M, Motoya S, Panaccione R, Torres J, Ungaro RC, Kligys K, Kalabic J, Zambrano J, Zhang Y, D'Haens G. Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies. Gastro Hep Adv. 2024 Mar 7;3(4):539-550. doi: 10.1016/j.gastha.2024.02.008. eCollection 2024.
- Derived from this study: PubMed 39105965Louis E, Lee WJ, Litcher-Kelly L, Ollis S, Pranschke E, Fitzgerald K, Lacerda AP, Neimark E, Sanchez Gonzalez Y, Panes J. Content Validity and Psychometric Evaluation of the Crohn's Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn's Disease. Adv Ther. 2024 Sep;41(9):3678-3705. doi: 10.1007/s12325-024-02923-9. Epub 2024 Aug 6.
- Derived from this study: PubMed 39054592Schreiber S, Cross RK, Panaccione R, D'Haens G, Bossuyt P, Dotan I, Colombel JF, Louis E, Dubinsky MC, Kligys K, Neimark E, Song A, Zambrano J, Kalabic J, Cheng E, Zhang Y, Ferrante M. Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease. Aliment Pharmacol Ther. 2024 Oct;60(7):897-906. doi: 10.1111/apt.18184. Epub 2024 Jul 25.
- Derived from this study: PubMed 37368103Dubinsky M, Ma C, Griffith J, Crowell M, Neimark E, Kligys K, O'Connell T. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease. Adv Ther. 2023 Sep;40(9):3896-3911. doi: 10.1007/s12325-023-02546-6. Epub 2023 Jun 27.
- Derived from this study: PubMed 37296268Loftus EV Jr, Ananthakrishnan AN, Lee WJ, Gonzalez YS, Fitzgerald KA, Wallace K, Zhou W, Litcher-Kelly L, Ollis SB, Su S, Danese S. Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative Colitis. Pharmacoecon Open. 2023 Sep;7(5):823-840. doi: 10.1007/s41669-023-00419-w. Epub 2023 Jun 9.
- Derived from this study: PubMed 35644154D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panes J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6.
- Related infoLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Related trials for Crohn's Disease
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
475 sites in 44 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing risankizumab IV and risankizumab SC in people with Crohn's Disease, run by AbbVie at 475 sites in 44 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 475 sites in United States, Japan, Germany, Canada, Italy and 39 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 6 Jul 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (time frame: Week 12). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03105128, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2022.